31 C
Vientiane
Wednesday, June 4, 2025
spot_img
Home Blog Page 385

Loft Logistics Ventures into Malaysia with New Warehouse


SINGAPORE – Media OutReach Newswire – 17 April 2025 – Loft Logistics, a 3PL logistics service provider in Singapore, is proud to announce its business expansion into Malaysia with a new warehouse in Shah Alam, Selangor.

Loft Logistics Shah Alam Warehouse
Loft Logistics Shah Alam Warehouse

Driving Growth in Southeast Asia

This strategic move enhances Loft’s capabilities, providing seamless logistics and fulfilment services that support businesses in both Singapore and Malaysia. Since its inception, Loft Logistics has envisioned a fully owned logistics network that services the Southeast Asia region. Given Malaysia’s close proximity to Singapore, it was the natural choice for the company’s first expansion. Encouraged by strong demand from Singapore-based customers, Loft Logistics is now in a prime position to facilitate cross-border trade.

Comprehensive Fulfillment Services in Malaysia

Loft Malaysia will offer the same services as its Singapore operations, ensuring consistency and efficiency for customers. These services include:

  • A customer control tower that will provide visibility of the inventory flow in both locations
  • Inbound management & quality inspections
  • Warehouse storage space for rent
  • Pick and pack operations
  • Bundling and kitting of items
  • Returns sortation, testing and product quality assessment
  • West Malaysia last-mile delivery (B2B and B2C)

Strategic Location: Shah Alam, Selangor

Shah Alam was chosen for its central location between Port Klang and Kuala Lumpur, with a travel time of approximately 35 minutes to either point. The area is well-connected by major expressways such as the Shah Alam Expressway (KESAS) and the Shah Alam Highway (LKSA), making it an ideal distribution hub for West Malaysia.

At the same time, Loft’s expansion presents a unique opportunity for Singaporean businesses looking to enter the Malaysian market. Key benefits include:

  • Consolidated inventory visibility in both Singapore and Malaysia for better stock allocation.
  • Streamlined cross-border trucking services to optimise inventory distribution between locations.
  • Reduced logistics costs by leveraging a localised fulfilment centre in Malaysia.

Supporting both Malaysian companies expanding into Singapore and Singaporean businesses entering Malaysia, Loft’s new warehouse in Shah Alam plays a key role in facilitating growth across the region. It focuses on improving distribution efficiency, providing scalable storage, and reducing delivery lead times within Malaysia. On top of that, businesses utilising these warehousing services can optimise costs by lowering shipping and import duty expenses.

“Our expansion into Malaysia is our initial step in a broader strategy for South East Asia in supporting local SMEs with an integrated cost effective logistics solution,” said Daryl Chan, Co-founder of Loft Logistics.

Unique Offerings in the Malaysia-Singapore Corridor

Loft provides specialised cross-border logistics services, facilitating operations for businesses trading between Singapore and Malaysia. Its offerings include temperature-controlled storage for sensitive products and end-to-end logistics solutions, covering warehousing to last-mile delivery. With an integrated system for real-time inventory tracking across both countries, businesses can manage their supply chains with greater visibility and efficiency.

Loft’s Next Chapter in Southeast Asia’s Logistics Landscape

With this expansion, Loft continues to provide businesses with the tools and infrastructure needed to scale successfully across borders. Stay tuned for further developments as the company moves forward with logistics network expansion in Southeast Asia.

“We have always been aiming to create a seamless logistics network to support businesses in scaling across borders. This expansion allows us to better serve our customers in the region” said Daryl Chan, Co-founder of Loft Logistics.
Hashtag: #loftlogistics





The issuer is solely responsible for the content of this announcement.

About Loft Logistics

Loft Logistics is a logistics company based in Singapore, specialising in storage solutions and fulfilment services tailored to e-commerce businesses. They provide flexible storage options and tech-enabled solutions to help businesses optimise their supply chains and improve operational efficiency.

Disney+ Coming Soon to Whale TV Models

Whale TV to Bring More Premium Entertainment to Whale TV Users Globally with Disney+ 

AMSTERDAM, April 17, 2025 /PRNewswire/ — Leading independent TV OS maker Whale TV™ and the Walt Disney Company have reached an agreement to bring Disney+ to Whale TV enabled smart TVs. Coming soon, on existing Whale TV devices, users will be able to add Disney+ from the app store and enjoy thousands of hours of premium entertainment content including popular titles such as Moana 2, Mufasa: The Lion King, Marvel Television’s Daredevil: Born Again, Lucasfilm’s Andor and more. On new Whale TV models, Disney+ will be available on the home screen upon startup. 

Disney+ Coming Soon to Whale TV Models
Disney+ Coming Soon to Whale TV Models

“Disney+ is one of the top global streaming services with a massive fandom, and is requested a lot by our users,” said Lucas Huang, VP Content Distribution at Whale TV. “We strive to offer the best of global and local services on our platform, so there is always something to watch for everyone.” 

Through the built-in app store, Whale TV users will soon be able to download the Disney+ app to their device. Users can then sign up through the app or sign in with their existing Disney+ subscription. Eligible consumers who purchase a Whale TV enabled television in Brazil and Panama will also be able to redeem a complimentary 12-month subscription to Disney+*. 

About Whale TV 

Whale TV is an independent TV operating system that makes TVs smart and simple to use. Since its inception in 2011, the company has worked with 400+ TV brands and enables 43.5M monthly active TVs around the world to help consumers discover, find and watch their favorite entertainment. With its easy-to-use TV OS, the company connects consumers, TV brands, content providers and advertisers. Whale TV is headquartered in Singapore and has teams collaborating across the globe to make TV better for everyone. 

About Disney+ 

Disney+ is the dedicated streaming home for movies and shows from Disney, Pixar, Marvel, Star Wars, and National Geographic, along with The Simpsons and much more. In select international markets, it also includes the general entertainment content brand, Star, and in the U.S., eligible bundle subscribers can also access select Hulu and ESPN+ content on Disney+**, including next day TV, Hulu and ESPN Originals, live sports events and studio programming. The direct-to-consumer streaming service from The Walt Disney Company,  Disney+ offers an unmatched collection of exclusive originals, including feature-length films, documentaries, live-action and animated series, and short-form content. With unprecedented access to Disney’s long history of incredible film and television entertainment, Disney+ is also the exclusive streaming home for the newest releases from The Walt Disney Studios. Disney+ is available as a standalone streaming service or as part of bundle offerings in the U.S. that give subscribers access to different combinations of Disney+, Hulu, and ESPN+. For more, visit disneyplus.com, or find the Disney+ app on most mobile and connected TV devices.

*Codes are not transferable and may be redeemed by new and returning Disney+ subscribers. Not a gift card. Valid only for residents within the Promotional Offer Territory, 18 years of age or older. Code entitles the holder to twelve (12)- month subscription of Disney+, which will be credited to your account upon redemption. To redeem, you must sign up using the customized link provided to you. A condition to redemption is that holder must create a new Disney+ account or reactivate an existing Disney+ account with a valid e-mail address and accept, if necessary, the Disney+ Subscriber Agreement. You can find the Disney+ Subscriber Agreement at: https://www.disneyplus.com/en-gb/legal/subscriber-agreement ***. Subscription to Disney+ requires a compatible internet device and internet connection. Code is one-time use only, and non-transferable. Void where prohibited. Cannot be combined with any other offers, coupons, discounts or promotions. Code is not refundable or redeemable for cash or any other goods or services and cannot be sold or transferred, or exchanged or credited towards purchase of other subscriptions, and will not be honored if obtained from any third party.

** ESPN on Disney+ requires a plan that includes ESPN+. Select Hulu content available via Disney+ with valid Hulu and Disney+ subscriptions; additional content only available via Hulu app. 18+ only. App feature, device restrictions, and terms apply.

 

Norgine welcomes TGA registration in Australia of IFINWIL® (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]

  • IFINWIL®: now TGA registered in Australia
  • Children diagnosed with neuroblastoma are on average just 2 years old2
  • The average survival rate of children with HRNB is only 50%2

UXBRIDGE, England, April 17, 2025 /PRNewswire/ — Norgine is pleased to announce that the Australian Therapeutic Goods Administration (TGA) has approved the registration of IFINWIL® (eflornithine) for the treatment of adults and paediatric patients with high-risk neuroblastoma (HRNB), who have responded to prior multiagent, multimodality therapy.1

Neuroblastoma Australia welcomed the news today:

On behalf of all families of children impacted by neuroblastoma, we welcome the TGA’s decision to approve IFINWIL®. We urgently need treatments for children diagnosed with neuroblastoma and this milestone marks a step in the right direction towards a better future for children and their families. We thank the Federal Government for taking action to ensure access and we look forward to continued support for children with aggressive cancers.” said Lucy Jones, CEO Neuroblastoma Australia.

High Risk Neuroblastoma is a rare but aggressive form of cancer, predominantly affecting children and most commonly presenting in the first 5 years of life2. Each year in Australia, approximately 50 children are diagnosed with neuroblastoma, with about half of these cases being classified as high risk neuroblastoma3,4. Neuroblastoma originates in the body’s nerve cells (neuroblasts) and typically presents as a primary tumour in the adrenal glands5. It is considered an aggressive tumour because it often spreads to other parts of the body (metastasizes). In most cases, it has spread by the time it is diagnosed5.

“We are committed to improving the lives of children and their families living with high-risk neuroblastoma” said Gus Rudolph, General Manager, Norgine, Australia. “This rare childhood cancer has devastating consequences for those impacted and while more needs to be done to improve treatment outcomes, we would like to recognise the TGA for their work to-date on this approval. Norgine will continue to engage with the relevant stakeholders to bring IFINWIL® to patients as quickly as possible.”

“This approval, as part of the Project Orbis initiative, represents a vital step forward in ensuring access to innovative cancer treatments for patients around the world,” said Dr. David Gillen, Chief Medical Officer, Norgine. “By working collaboratively with international regulatory partners, we are able to help bring promising therapies to paediatric patients sooner – a goal that is especially important when time is critical. We’re proud to support Project Orbis as we strive to expedite access to high-impact oncology medicines.”

Receiving the TGA approval is an important milestone on the path to realising sustainable and equitable access. IFINWIL® is not currently included on the PBS.

Please refer to the IFINWIL® Consumer Medicines Information (CMI) for full safety information on risks, side effects and precautions including the risk of low red blood cells (anaemia), low neutrophils (blood cells that fight infection), low platelets (clotting cells), increase in liver enzymes, and hearing loss or problems balancing.1

Notes to Editors:

About IFINWIL®

IFINWIL® has been investigated for use as a post maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients with no active disease (NAD) / no evidence of disease (NED) after first line multiagent, multimodality therapy.6 IFINWIL® is a therapy that blocks an enzyme called ornithine decarboxylase (ODC) responsible for producing polyamines, which are important to tumour growth and development 7.

For more information on IFINWIL®, find the CMI here: IFINWIL Consumer Medicine Information (CMI) or the Therapeutic Goods Administration at https://www.tga.gov.au/ or speak to your healthcare practitioner.

High-Risk Neuroblastoma (HRNB) Treatment Background

Children diagnosed with HRNB undergo an intense treatment regimen that still leaves them vulnerable to relapse and death.8 Although there have been some improvements in survival, children with high risk neuroblastoma still face a 30% chance of recurrence (relapse) within the first 5 years post maintenance, and have an extremely poor prognosis and low likelihood of long term survival9 (e.g. estimates as low as 15% of patients will live for five years after relapsing).10 Avoiding relapse is key to long-term survival, and until now, there have been no approved therapies for the post maintenance treatment period in major markets outside of the United States11.

About Project Orbis

Project Orbis is an initiative (since May 2019) of the US FDA Oncology Center of Excellence (OCE) and provides a framework for concurrent submission and collaborative review of innovative oncology products among international regulatory authorities. It was created with the overarching goal to speed worldwide patient access to innovative cancer therapies. Project Orbis is coordinated by the FDA, and its partners include United Kingdom Medicines and Healthcare Products regulatory Agency (UK MHRA), Australia Therapeutic Goods Administration (TGA), Canada (Health Canada), Singapore (Health Sciences Authority (HSA), Switzerland (Swissmedic), Brazil (Agência Nacional de Vigilância Sanitária (ANVISA), Israel (Ministry of Health).

In April 2024, Norgine submitted an application for approval of eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland and the United Kingdom. This milestone supports Norgine’s efforts to deliver patient access to eflornithine and bring a further treatment option in the field of paediatric oncology.

About Norgine

Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people’s lives drives everything we do, and our European experience, fully integrated infrastructure and exceptional partnership approach enable us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped more than 25 million patients around the world in 2022 and generated €530 million in net product sales, a growth of nearly 5% over 2021.

Norgine has a direct presence in 16 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets. We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

References

  1. Australian Product Information, IFINWIL®: IFINWIL Product Information (PI). Accessed 16.04.25
  2. https://www.neuroblastoma.org.au/about-key-statistics. Accessed 26.03.25
  3. Australian Childhood Cancer Registry, Cancer Council Queensland. Australian Childhood Cancer Statistics Online (1983-2021). CCQ: Brisbane, Australia; October 2024.
  4. ANZCHOG-Position-Statement-Eflornithine-DFMO-use-for-patients-with-high-risk-neuroblastoma-in-Australia-and-New-Zealand-v2.0-23.08.2024.pdf
  5. https://rarediseases.info.nih.gov/diseases/7185/neuroblastoma. Accessed 16.03.25
  6. Clinical Trial NCT02395666; Preventative trial of difluoromethylornithine (DFMO) in high risk patients with neuroblastoma that is in remission. Available from: Study Details | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | ClinicalTrials.gov.
  7. Meyskens FL Jr, Gerner EW. Clin Cancer Res. 1999 May;5(5):945-51. 4. Sholler GLS, et al. Sci Rep. 2018 Sep 27;8(1):14445.
  8. Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115:1048-57.
  9. Desai A, et al. J Clin Oncol. 2022 Jul; JCO2102478. 2. Lewis EC, et al. Int J Cancer. 2020 Dec;147(11):3152-3159
    Bagatell R, DuBois SG, Naranjo A, et al. Children’s Oncology Group’s 2023 blueprint
  10. London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer. 2017;123:4914-23.
  11. FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA, Accessed 02.04.25

Norgine strengthens rare disease portfolio with acquisition of Theravia

Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine’s strategy for sustainable growth, adding a complementary portfolio of rare disease medicines

Transaction further establishes Norgine’s position as a partner of choice for commercialising rare and specialty pharmaceuticals in Europe

PARIS, April 17, 2025 /PRNewswire/ — Norgine and Theravia announced today that they have entered into a definitive agreement under which Norgine will acquire Theravia, an international pharmaceutical company specialising in cutting-edge treatments for patients with rare and debilitating conditions.

Recent deals with Fennec Pharma for PEDMARQSI® and X4 Pharma for mavorixafor demonstrate Norgine’s strong emphasis on driving growth in rare disease and specialty medicines through acquisitions and in-licensing.

Theravia’s innovations have resulted in successful launches of life-saving medications which have changed patient outcomes worldwide. Theravia has several products in the rare disease space, including SIKLOS®, for adults and children with sickle cell disease, and ORPHACOL®, a medicine for adults and children who have a genetic disorder that affects bile production by the liver. These products span both the rare haematology and rare hepatology therapeutic areas and are complementary to Norgine’s existing rare and specialty portfolio. The development of Theravia in the past few years has been supported by its majority shareholder Mérieux Equity Partners, a healthcare dedicated investment firm based in France.

This acquisition is a unique opportunity for Norgine to bolster our growth trajectory, as well as our rare disease portfolio.” said Janneke van der Kamp, Chief Executive Officer, Norgine. “With our strong legacy and proven track record of successfully bringing innovative treatments to patients, we believe we are well placed to ensure the Theravia medicines reach their full potential.”

Franck Hamalian, Chief Executive Officer, Theravia, added: “The joining of our companies brings together the skills, know-how and geographical presence that will create a European-based champion of rare and ultra rare disease. Our combined product portfolios and Norgine’s legacy and experience will enable broader access to medicines for patients with high unmet medical needs.”

With the acquisition of Theravia, Norgine will now have six core products in its rare disease portfolio (PEDMARQSI®, eflornithine, mavorixafor, AGILUS®, SIKLOS® and ORPHACOL®) thereby comprising a franchise of critical scale with the ability to be a key growth driver in the medium-to-long-term.

Norgine looks forward to building on this transaction as we continue to strengthen our platform for future acquisitions and in-licensing opportunities to drive growth.

The transaction remains subject to obtaining customary regulatory approvals from the competent authorities.

Notes

About Theravia
Theravia is an international pharmaceutical laboratory specializing in rare or neglected diseases. Formed through the merger of Addmedica and CTRS, Theravia is dedicated to addressing the unmet medical needs of patients with these challenging conditions.

About SIKLOS®
SIKLOS® is used in adults, adolescents and children over two years of age who have sickle-cell syndrome, a genetic disease where the red blood cells become rigid and sticky and change from being disc-shaped to being crescent-shaped (like a sickle). It is used to prevent recurrent, painful vaso-occlusive crises that happen when blood vessels become blocked by the abnormal red blood cells, restricting the flow of blood to an organ. They can include acute chest syndrome, a life-threatening condition when the patient has sudden chest pain, fever, hard breathing or signs of fluid in the lungs on an X-ray.

SIKLOS® is marketed in 17 countries around the world.

About ORPHACOL®
ORPHACOL® is a medicine containing cholic acid, a substance found in the bile, which is used to digest fats. It is approved in the US and Europe used to treat adults and children from one month of age who have a genetic abnormality that makes them unable to produce bile. The therapy is used in patients who do not have enough of two specific liver enzymes which makes their liver unable to produce enough of the main components of bile, called primary bile acids, such as cholic acid. When these primary bile acids are lacking, the body produces abnormal bile acids instead which can damage the liver, potentially leading to life-threatening liver failure.

ORPHACOL® is marketed in 23 countries around the world.

About PEDMARQSI®
PEDMARQSI® is a novel formulation of anhydrous sodium thiosulfate, specifically developed and manufactured for the prevention of cisplatin-induced hearing loss in patients 1 month to <18 years of age. It is the first and only preventative treatment developed for cisplatin-induced ototoxicity to support children and adolescent patients with localised, non-metastatic solid tumour cancers.

It was granted marketing authorisation by the EMA in May 2023 (under the paediatric-use marketing authorisation (PUMA) programme) and the MHRA in October 2023.

About Mavorixafor
Mavorixafor is a selective CXCR4 receptor antagonist approved in the U.S. and marketed by X4 as XOLREMDI®, an oral, once-daily treatment for patients 12 years of age and older with WHIM syndrome, a rare primary immunodeficiency.

In January 2025, X4 submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for mavorixafor for the treatment of WHIM syndrome, for which it has been granted Orphan Drug Designation by both the EMA and the U.S. Food and Drug Administration.

X4 is also developing the medicine to treat chronic neutropenia (CN) and is currently conducting a global, pivotal Phase 3 clinical trial in certain CN disorders. Norgine has responsibility for commercialisation in Europe, Australia, and New Zealand following regulatory approvals.

About Eflornithine
Eflornithine has been investigated for use as a post maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients with no active disease (NAD) / no evidence of disease (NED) after first line multiagent, multimodality therapy. It is a targeted therapy that blocks an enzyme called ornithine decarboxylase (ODC), responsible for producing polyamines, which are important to tumour growth and development.

The medicine is approved by the FDA for a maintenance therapy for high-risk neuroblastoma in adult and pediatric patients. In April 2024, an application for approval was submitted by Norgine for the use of eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland and the United Kingdom. In January 2025, a marketing authorisation application was filed to the European Medicines Agency (EMA) for the medicine in high-risk neuroblastoma (HRNB).

About AGILUS®
AGILUS® is a medicine used to treat malignant hyperthermia (rapid rise in body temperature caused by uncontrolled muscle contractions) in adults and children. Malignant hyperthermia is a serious reaction to certain medicines used for general anaesthesia during surgery or other medical procedures.

AGILUS® is approved for use by the EMA for for the treatment of malignant hyperthermia in adults and children in combination with adequate support measures.

About Mérieux Equity Partners
Founded in 2009, Mérieux Equity Partners (“MxEP”) is a leading European healthcare-specialized investment firm, with two dedicated platforms, Venture Capital and Buyout, supporting companies ranging from start-ups to established leaders. Benefiting from a longstanding expertise and a large network, MxEP invests in companies with ambitious growth projects and transformative products or services in healthcare. MxEP is AMF-accredited and currently manages c.€1.5bn of AuM.

About Norgine
Norgine is a uniquely positioned, specialty pharmaceutical and consumer healthcare company, with over €550 million of annual revenues and a 120-year track record of bringing life-changing products to patients and consumers across our core markets of Western Europe, Australia and New Zealand.

Norgine’s integrated approach – strong commercial capabilities, as well as deep medical, regulatory and clinical expertise, in-house manufacturing, robust supply networks, and best-in-class enabling functions – ensures that Norgine can deliver high-quality, transformative medicines quickly and effectively to over 25 million patients annually.

Norgine is a nimble, innovative, and high-performing company that has been transformed by a relentless focus on operational excellence. This focus will enable us to secure the legacy of more than a century of innovation and doing the right thing by our patients, as we push the boundaries and take strides into therapeutic innovation.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

 

Creality Brings Its ShareFest Back to New Zealand to Celebrate the Maker Spirit

AUCKLAND, New Zealand, April 17, 2025 /PRNewswire/ — Creality, a global leader in the 3D printing industry, brought its community event ShareFest back to “the city of sails” of Auckland and attracted more than 100 people to celebrate this yearʼs theme — “To Makers. By Makers.”

Auckland Makers unite to celebrate ShareFest 2025
Auckland Makers unite to celebrate ShareFest 2025

A Festival of Multi-layered Fun

The 2025 fan gathering in New Zealand is a joint effort by Creality and PB Tech — one of Australasia’s largest computing and technology resellers.

At the event, Creality showcased its latest innovations — K2 Plus, Creality Hi, Ender-5 Max, Falcon A1, and the new slicer software Creality Print 6.0. Apart from an exclusive product hands-on experience, the community members participated in interactive games like a quick quiz that included a variety of 3D printing questions, and the “Make & Match” to assemble a 3D printed Creality logo. The event also saw inspiring speeches from invited industry experts, along with an open discussion where everyone was encouraged to share everything about their experience with 3D printing. Last but not least, the event culminated in the 3D printed model contest where all makersʼ creativity shines the brightest.

Powerful Industry Insights

Invited speakers from vastly different fields shared their takes on how 3D printing has made a huge difference in both their professions and hobbies.

  • Carl Salas — Lecturer at the Unitec School of Architecture
    Carl shared how 3D printing is rapidly changing the landscape of architectural design, cultivating architects with the mindset to think outside the box.
  • H + R Drone Racing — Drone Lovers & Content Creators
    The drone-loving twins started a YouTube channel to document their DIY projects — from RC submarines, drones and FPVs to an RC wingsuit. Fueled by a passion for turning out-of-this-world ideas into reality, they’ve brought many maker projects to life.

Model Contest Highlights

With over 20 models vying for 3 top spots, this year’s contest was intense. Meet the winners:

  1. 1st Place: R2-D2 by John Ferguson
    John won with his 365-day project — a remote-controlled, talking R2-D2 from Star Wars, printed all on a Creality Ender-5.
  2. 2nd Place: Yarn Tools by Terri Cattell
    A retiree, grandma, and ShareFest second-timer, Terri got a K1 Max printer as a gift just last year, and amazed everybody at the event with her 3D printed yarn swift — a combination of her long-time and new-found hobbies.
  3. 3rd Place: BB-8 & EVE by Mike Owen
    A 1:1 BB-8 replica that is fully animatronic.

Incredible Energy from Makers

The ShareFest is held at the PB Tech store in Manukau, located in the suburb of Auckland, where product manager Joe Shi expressed his excitement:

“The energy today was incredible — far beyond what we imagined! Seeing so many passionate makers, from veteran creators like John to inspiring newcomers like Terri, reminds us why we do this. Together with Creality, we’re proud to foster a culture where ‘By Makers. To Makers’ comes to life. The feedback has been overwhelming, and we can’t wait to bring even more innovation to our next ShareFest!”

About Creality

Founded in Shenzhen in 2014, Creality is a global pioneer in the 3D printing industry that focuses on the research, design, and production of consumer and professional-grade 3D printers and 3D printing accessories. ShareFest is a global community event hosted by Creality.

Creality has officially launched an Instagram account dedicated to 3D printing hobbyists in New Zealand & Australia. Follow creality_anz to know more. 
https://www.instagram.com/creality_anz/

Media contact: brand@creality.com

K-Beauty Trouble-Care Leader ‘Fation’ Debuts Nosca9 Deep Pore Cleanser in the U.S., Laying the Foundation for Glass Skin

SEOUL, South Korea, April 17, 2025 /PRNewswire/ — Korean skincare favorite Fation, the top-rated trouble-care brand at Olive Young with a near-perfect 4.9/5.0 rating, has officially launched in the U.S. market. Next rookie following after its best selling ‘Trouble’ Line, the Nosca9 Deep Pore Cleansing Foam, hit Amazon in March—and the response has been immediate. Named an Amazon “Overall Pick” and boasting an average rating above 4.7 stars, the product is already gaining momentum among beauty enthusiasts looking to achieve the Korean “glass skin” look.

K-Beauty Trouble-Care Leader ‘Fation’ Debuts Nosca9 Deep Pore Cleanser in the U.S., Laying the Foundation for Glass Skin
K-Beauty Trouble-Care Leader ‘Fation’ Debuts Nosca9 Deep Pore Cleanser in the U.S., Laying the Foundation for Glass Skin

What sets this cleanser apart is its key ingredient: Retinal—a highly functional next-generation powerhouse often described as a more effective and less irritating upgrade to the widely known Retinol. Rare to use on the cleanser category but backed by the unique technology of Dong-A Pharmaceutical, a leading name in Korea’s pharmaceutical industry for over 94 years, Fation’s proprietary Nano-Retinal RX Complex™ delivers visible pore-tightening benefits with dermatologist-grade precision.

In addition to Retinal, the formula includes rice extract, 17 types of amino acids, and a tannin complex for a well-rounded, skin-friendly deep cleanse. The unique, stretchy texture clings to impurities and excess oil, helping to refine skin texture and minimize enlarged pores.

In celebration of its successful U.S. debut, Fation is offering a limited-time Amazon promotion from April 14 to 23, slashing the price from $15.99 to $11.19 (30% Off).

The Nosca9 line is just the beginning. Fation’s Trouble Soothing range—including toner, serum, cream, and masks for sensitive or acne-prone skin—is also available on Amazon.

Explore the full collection:
Cleansing Foam: https://amzn.to/44vKTGi
Serum Set: https://amzn.to/3EfyVpP
Cream S: https://amzn.to/4lsXVuf
Toner S: https://amzn.to/42cCzKk
Real Fit Mask: https://amzn.to/4ju9AY1
Glass skin starts here—with Fation.

Spring Into Savings: VARON Offers Discounts on Oxygen Solutions for Allergy Season

NEW YORK, April 17, 2025 /PRNewswire/ — As spring blooms across the country, so does allergy season — a time when pollen, dust, and airborne irritants can aggravate respiratory conditions and make breathing more difficult. VARON, a leading provider of respiratory care solutions, is helping consumers combat these seasonal challenges with advanced oxygen concentrators and exclusive spring savings.

To support customers during peak allergy season, VARON has launched its Spring Sale, offering sitewide discounts of up to 30% on select oxygen concentrators and accessories. The promotion is aimed at helping more people access reliable respiratory support while enjoying significant savings.

How Spring Allergies Affect Breathing

Each year, millions of Americans experience allergic rhinitis, commonly known as hay fever. For individuals living with asthma, chronic obstructive pulmonary disease (COPD), or other respiratory conditions, exposure to spring allergens can worsen symptoms such as wheezing, congestion, and shortness of breath.

Oxygen therapy has become a trusted solution for improving respiratory health, ensuring users receive adequate oxygen while reducing exposure to airborne allergens.

VARON Oxygen Concentrators: Breathing Easier This Spring

VARON’s oxygen concentrators are engineered with advanced filtration systems to deliver purified oxygen while minimizing irritants. Key features include:

  • Enhanced Air Filtration: Removes pollen, dust, and other allergens from the air.
  • Built-in Humidification: Adds moisture to oxygen to prevent dryness and irritation.
  • Continuous and Pulse Flow Options: Customized oxygen delivery for every need.
  • Portable, Lightweight Design: Ideal for users staying active indoors or outdoors.

These healthcare devices offer a convenient solution for individuals seeking respiratory support at home or on the go.

Spring into Savings: Limited-Time Discounts Now Available

In celebration of spring, VARON’s Spring Sale offers exclusive savings to help more customers access essential respiratory care solutions.

Customers can take advantage of:

  • Up to 30% off on featured oxygen concentrators and respiratory accessories
  • 18% off sitewide with no code required
  • Free shipping on all orders

Whether planning outdoor adventures, family gatherings, or simply enjoying fresh air in comfort, VARON’s oxygen concentrators help users breathe easier and embrace the season.

For more details on VARON’s Spring Sale or to explore its oxygen therapy solutions, visit https://varoninc.com or contact support@varoninc.com.

Essential Maintenance Tips for Optimal Performance and Hygiene

In addition to the promotions, VARON is encouraging customers to take this opportunity to care for their oxygen equipment. “Regular maintenance of oxygen devices and accessories plays a vital role in ensuring safe, effective, and comfortable oxygen therapy,” said Dr. Walkers, Director of Product Development at VARON. “Over time, components like filters and cannulas can accumulate dust, moisture, and bacteria, which may affect both air quality and the overall user experience.”

VARON recommends the following spring maintenance checklist:

1. Replace Air Filters

Filters help block dust, debris, and airborne particles from entering the device. Replacing them every 3 months (or more frequently in dusty environments) ensures clean air intake and protects internal components.

2. Change Nasal Cannulas and Tubing

These components are in direct contact with the user and can harbor bacteria if not changed regularly. It is recommended to replace cannulas every 2-4 weeks, based on your frequency of use, to maintain hygienic oxygen delivery.

3. Clean Accessories Weekly

Wash cannulas, tubing, and humidifier bottles (if applicable) weekly using mild soap and warm water, then allow them to air dry completely. Never use harsh chemicals or alcohol.

4. Inspect and Replace Batteries (for Portable Units)

If using a portable concentrator, check battery life and replace older batteries that no longer hold a full charge. Proper battery function is essential for uninterrupted oxygen therapy on the go.

5. Store Devices Properly

Keep equipment in a clean, dry place when not in use. Avoid direct sunlight, excessive heat, or moisture to prevent internal damage and preserve the unit’s integrity.

Customers can find replacement filters, cannulas, tubing, and batteries available at discounted prices during the Spring Sale.

Supporting Health and Wellness Year-Round

In addition to providing high-quality respiratory equipment, VARON encourages customers to take proactive steps to manage allergy symptoms during spring. These include using air purifiers indoors, limiting outdoor exposure during peak pollen hours, staying hydrated, and consulting healthcare providers for personalized care plans.

VARON remains committed to supporting respiratory wellness with products designed for comfort, efficiency, and reliability.

About VARON

VARON is a trusted leader in respiratory care, providing innovative oxygen therapy solutions to support individuals with chronic and seasonal breathing difficulties. Committed to comfort, reliability, and cutting-edge technology, VARON helps users around the world breathe easier every day.

Media Contact:
Winnie Li
official@varoninc.com 

2026 Best Lawyers® in Australia showcases law firm talent, highlights Brisbane as emerging hub for top legal minds

New data from Best Lawyers reveals top-ranked legal talent across Australia, providing insights for firm marketing and recruitment

AUGUSTA, Ga., April 17, 2025 /PRNewswire/ — Best Lawyers® today announces the release of the 2026 editions of The Best Lawyers in Australia™ and Best Lawyers: Ones to Watch in Australia™, offering law firms a powerful resource to benchmark professional excellence, spotlight emerging legal talent and strengthen their competitive standing.

2026 editions of The Best Lawyers in Australia™
2026 editions of The Best Lawyers in Australia™

The Best Lawyers rankings, representing the country’s top 5% of legal talent1, offer data-driven insights and access to a global network that Australian legal firms can leverage to support their marketing, recruitment and client development initiatives.

Best Lawyers CEO, Phillip Greer, said the 18th edition of The Best Lawyers in Australia recognises more than 4,500 lawyers selected from a rigorous peer-review process. Of those, 314 lawyers are being honoured for the first time, reflecting the continued expansion in this region.

Now in its fourth year, Best Lawyers: Ones to Watch in Australia highlights more than 790 early-career lawyers for outstanding professional achievement.

In addition, 329 nominees were awarded the prestigious “Lawyer of the Year” title, for those receiving the highest overall peer feedback for a specific practice area and geographic region.

“The Australian legal market continues to advance, with seasoned lawyers and emerging voices leading the charge on some of the globe’s most pressing legal challenges,” Mr Greer said.

“From class actions and data privacy to climate-related litigation, this year’s Australian honorees represent the highest calibre of the profession, with a growing focus on impact, innovation and accountability.”

Sydney and Melbourne dominance challenged

Sydney, Melbourne and Brisbane lead the country in awarded talent, underscoring their roles as Australia’s primary legal and commercial hubs – but there are emerging trends as to where top legal talent is concentrated, according to Best Lawyers Vice President of Research and Development, Elizabeth Petit.

Brisbane has emerged as a growing hub, attracting a rising number of high-performing legal professionals – likely driven by the city’s population growth, economic development and expanding legal market.

Sydney and Melbourne maintain their long-standing reputations as powerhouses for top legal talent, however their growth has not been as dramatic,” she said.

Litigation remains the most recognised practice area in the 2026 editions, followed by Insurance Law and Alternative Dispute Resolution, reflecting growing legal needs across corporate, risk and strategic advisory services.

Mr Greer said legal firms across Australia continue to demonstrate a commitment to professional distinction, with 700 firms represented this year and a record 500,000 evaluations made in the peer-review process required for nominees.

“Best Lawyers’ recognition process is a key indicator of legal expertise and credibility for clients and the broader legal profession, providing valuable third-party validation in a highly competitive industry.

“Our peer rankings provide a confirmed network for people to tap into and know they are getting the best legal representation,” he said.

Further strengthening its position in the Australian legal market, Best Lawyers will announce the 2026 Best Law Firms™ – Australia and release its Australian Legal Market Report providing a comprehensive overview of legal trends on May 29, 2025.

Search The Best Lawyers in Australia and Best Lawyers: Ones to Watch in Australia results by lawyer name, firm, region and/or practice area by visiting www.bestlawyers.com.

About Best Lawyers®

Best Lawyers® is the most established global network of legal professionals, providing elite lawyers and law firms with tools to enhance visibility, credibility and client engagement. Built on a rigorous peer-review process, Best Lawyers delivers data-driven legal recognition while offering industry insights and tech-forward marketing solutions. Powering Best Law Firms®, we simplify the law firm selection process, fostering confidence between firms and clients. Learn more at www.bestlawyers.com and www.bestlawfirms.com.

Australian Media Contacts:

Kathryn Britt

Laura Aguayo

Group Client Manager

Account Leader

BBS Communications Group

BBS Communications Group

kbritt@bbscommunications.com.au

laguayo@bbscommunications.com.au

Ph: 0414 661 616

Ph: 0433 531 074

US-based Contact:

Alliccia Odeyemi
Senior Public Relations Manager
aodeyemi@bestlawyers.com

1 The number of honored individuals divided by 90,000 lawyers practicing (as reported by Statista).

Photo – https://laotiantimes.com/wp-content/uploads/2025/04/best_lawyers__2026_editions_of_the_best_lawyers_in_australia.jpg

Logo – https://laotiantimes.com/wp-content/uploads/2025/04/best_lawyers_logo.jpg